Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.178,04
-0,88%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Kazia Therapeutics Ltd (KZIA) Kazia Therapeutics Ltd (KZIA) Notizie

Kazia Therapeutics Ltd

KZIA
0,3887
0,01875 (5,07%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
21/3/202413:52PRNUSKazia Therapeutics licenses paxalisib to Sovargen for..
13/3/202413:00PRNUSKazia announces presentation of new data at AACR Annual..
21/2/202422:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21/2/202415:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202413:30PRNUSKazia Therapeutics Reports Early Conclusion of Clinical..
14/2/202421:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202400:35EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
05/2/202422:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/1/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202413:30PRNUSKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
12/1/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/12/202323:26EDGAR2Form F-3 - Registration statement by foreign private issuers
06/12/202314:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202300:02PRNUSKazia Therapeutics Announces Closing of $2 Million..
04/12/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/12/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202314:00PRNUSKazia Therapeutics Announces $2 Million Registered Direct..
29/11/202322:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202313:01PRNUSKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE..
21/11/202313:30PRNUSKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS..
20/11/202322:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202322:30PRNUSKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
15/11/202315:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/11/202314:30PRNUSKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY..
10/11/202313:01PRNUSKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS..
01/11/202321:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202312:01PRNUSKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING..
26/10/202313:56EDGAR2Form 20-F - Annual and transition report of foreign private..
23/10/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM..
13/10/202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202313:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202313:01PRNUSKazia announces voluntary delisting from ASX
10/10/202321:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING..
29/9/202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING..
29/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202313:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/7/202313:00PRNUSKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA..
08/6/202313:00PRNUSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO..
25/5/202313:01PRNUSKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE..
Apertura: 0,3646 Min: 0,357 Max: 0,389
Chiusura: 0,36995

La tua Cronologia

NASDAQ
KZIA
Kazia Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network